Harley H.Y. Kwok

Harley H.Y. Kwok

Auto-generated profile, based on publicly available information

Harley H.Y. Kwok

School of Public Health, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in eClinicalMedicine
Verified
Journal Article
Open access
DTDaira Trusinska
Daira Trusinska
BLBohee Lee
Bohee Lee
SFSohail Ferdous
Sohail Ferdous
HKHarley H.Y. Kwok
Harley H.Y. Kwok
BGBecky Gordon
Becky Gordon
TSTing Shi
Ting Shi
In clinical trials, recently introduced respiratory syncytial virus (RSV) immunisation products have shown high efficacy in preventing severe RSV outcomes. Implementing successful immunisation programmes is however key to realising these benefits in real-world settings. We aimed to investigate uptake of the long-acting monoclonal antibody nirsevimab, the RSV maternal vaccine, and RSV vaccines for older adults in countries where immunisation programmes have been introduced, and to explore how uptake varies between countries and population subgroups. In this systematic review and meta-analysis, we carried out four monthly searches in Medline, Embase, and Global Health databases for studies reporting uptake of nirsevimab, the RSV maternal vaccine, and RSV vaccines for older adults. We included population-based studies published between December 1, 2022 and February 5, 2025. Two independent reviewers screened studies, extracted data, and completed a risk of bias assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. We assessed uptake stratified by country and socio-demographic and clinical subgroups. Meta-analyses were conducted using random-effects modelling. PROSPERO registration number: CRD42025643585. We screened a total of 1267 studies, 43 of which met the inclusion criteria reporting data on over 1.38 million individuals from six countries. Nirsevimab uptake data were reported in 34 studies: 16 from Spain, eight from the United States, seven from France, one with combined data from Andorra and Spain, and one from each of Italy and Luxembourg. Our pooled estimates showed that nirsevimab uptake on population level was 90.1% (95% confidence interval (CI): 86.4–92.9) in Spain and 51.2% (95% CI: 29.3–72.7) in the United States during the 2023/24 RSV season. Uptake data for the RSV maternal vaccine and RSV vaccines for older adults were reported in five and eight studies, respectively, all from the United States. Meta-analysis showed population-level uptake of 30.5% (95% CI: 20.6–42.6) and 18.2% (95% CI: 10.8–28.9), respectively. Uptake varied across subgroups. Uptake of nirsevimab varied substantially between the countries that have implemented infant RSV immunisation programmes. Despite the limited number of studies and the lack of more accurate data at national level the low uptake estimates for RSV maternal vaccine and RSV vaccines for older adults are concerning. National, clinical, and public health initiatives are needed to increase uptake of RSV immunisation products and ensure maximum benefit to people currently at risk of severe RSV outcomes. 10.13039/501100023699 Health Data Research UK , Inflammation and Immunity Driver Programme.

14 January 2023 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
JQJianchao Quan
Jianchao Quan
ZZZhenping Zhao
Zhenping Zhao
LWLimin Wang
Limin Wang
CNCarmen S. Ng
Carmen S. Ng
HKHarley H.Y. Kwok
Harley H.Y. Kwok
MZMaigeng Zhou
Maigeng Zhou
The prevalence of diabetes has risen sharply in China. Improving modifiable risk factors such as glycaemia and blood pressure could substantially reduce disease burden and treatment costs to achieve a healthier China by 2030. We used a nationally representative population-based survey of adults with diabetes in 31 provinces in mainland China to assess the prevalence of risk factor control. We adopted a microsimulation approach to estimate the impact of improved control of blood pressure and glycaemia on mortality, quality-adjusted life-years (QALYs), and healthcare cost. We applied the validated CHIME diabetes outcomes model over a 10-year time horizon. Baseline scenario of status quo was evaluated against alternative strategies based on World Health Organization and Chinese Diabetes Society guidelines. Among 24,319 survey participants with diabetes (age 30–70), 69.1% (95% CI: 67.7–70.5) achieved optimal diabetes control (HbA1c <7% [53 mmol/mol]), 27.7% [26.1–29.3] achieved blood pressure control (<130/80 mmHg) and 20.1% (18.6–21.6) achieved both targets. Achieving 70% control rate for people with diabetes could reduce deaths before age 70 by 7.1% (5.7–8.7), reduce medical costs by 14.9% (12.3–18.0), and gain 50.4 QALYs (44.8–56.0) per 1000 people over 10 years compared to the baseline status quo. The largest health gains were for strategies including strict blood pressure control of 130/80 mmHg, particularly in rural areas. Based on a nationally representative survey, few adults with diabetes in China achieved optimal control of glycaemia and blood pressure. Substantial health gains and economic savings are potentially achievable with better risk factor control especially in rural settings. Chinese Central Government, Research Grants Council of the Hong Kong Special Administrative Region, China [27112518].

1 May 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
HKHarley Kwok
Harley Kwok
GMGeorgie Massen
Georgie Massen
AAAlexander Adamson
Alexander Adamson
CKConstantinos Kallis
Constantinos Kallis
ALAdam Lahmami
Adam Lahmami
JQJennifer Kathleen Quint
Jennifer Kathleen Quint
Medical codes and codelists are essential to identify diseases, medicines, and related events when using electronic healthcare records (EHRs) for research. As multiple codes can be used to define the same medical condition, an inconsistency of applying codes by clinicians or researchers may complicate the identification of diseases. To minimize the inconsistency of codes and increase the comparability of research findings, we sought to integrate all medical codes and codelists generated from existing studies to produce a single list of codes for both chronic bronchitis and emphysema for future research. We systematically reviewed studies, which included codes used to define chronic bronchitis and/or emphysema regardless of code systems. We searched MEDLINE, Embase, Web of Science, Scopus, CINAHL, and Global Health from 1st January 2000 to May 2024 for relevant studies. Medical codes or codelists were identified, extracted, and compiled into single codelists for chronic bronchitis and emphysema separately based on their frequency of appearance across all included studies (PROSPERO: CRD42024529169). We identified 18 studies containing codelists, from a total of 1082 studies. Only International Classification of Disease (ICD) codes were found in studies, which defined chronic bronchitis and emphysema. Chronic bronchitis was defined as 490 and 491 in ICD-9 and J40, J41, J42, and J44 in ICD-10. Meanwhile, emphysema was defined as 492 in ICD-9 and J43 in ICD-10. Additionally, to fill the current gap, we created SNOMED CT codelists for both chronic bronchitis and emphysema, to standardize the definitions of these diseases in future studies.

6 March 2026 in Chronic Respiratory Disease
Verified
Journal Article
Open access
AAAlexander Adamson
Alexander Adamson
HKHarley Kwok
Harley Kwok
SSSally J. Singh
Sally J. Singh
TWTom M. A. Wilkinson
Tom M. A. Wilkinson
HDHolly Drover
Holly Drover
JQJennifer K. Quint
Jennifer K. Quint
Objectives: Home-based pulmonary rehabilitation (PR) is increasingly offered as an alternative to centre-based PR. This study explores differences in the characteristics of people with COPD enrolling in home-based versus centre-based PR in England and Wales and assesses whether availability of home-based PR is associated with increased enrolment. Methods: This study used data from the UK 2023-24 National Respiratory Audit Programme PR audit. Eligible people had a primary condition of COPD, complete mental health and geographic data, and attended an initial assessment at a centre that completed the clinical and organisational audit. For the primary analysis only, people were further restricted to those enrolled on a purely home-based or centre-based programme at a centre that offered both options. Enrolment was defined as having attended an initial assessment and having at least one scheduled PR session with a defined start date. Differences in characteristics were assessed using Chi-square and Kruskal-Wallis tests. The association between availability of home-based PR and enrolment was assessed using a mixed-effects logistic regression model. Results: 13719/29981 (45.8%) people were eligible for inclusion in the primary analysis and 25039/29981 (83.5%) were eligible for the secondary analysis. Those who enrolled in a home-based programme were more likely to: be female (58.6% vs 48.2%; p<0.001); be more deprived (55.7% versus 46.6% in IMD quintiles 1 or 2, p<0.001); have a greater mental health burden (28.2% versus 22.2% with at least 1 cognitive impairment recorded, p<0.001); and classified their symptom burden as more severe at assessment (CAT score 23 versus 22, p <0.001). Home-based PR was unavailable for 9099/25039 (36.3%) people. Availability of home-based PR was not associated with reduced non-enrolment in PR when compared with centres that did not offer home-based PR (adj-OR for non-enrolment: 0.79; 95%CI:0.51-1.23)). Conclusion: Healthcare providers and those developing home-based PR digital applications should consider tailoring their approach to those who are most likely to opt in, who tend to be younger, female, and have a higher burden of respiratory symptoms and mental health comorbidities.